Labcorp Holdings Inc.
LH Healthcare Medical - Equipment & Services NYSE
$269.67
$-6.25 (-2.27%)
Open: $273.38 | High: $274.16 | Low: $267.78 | Prev Close: $275.92
Market Cap: $22.36B
Volume: 370K | Avg: 709K
Last updated: March 09, 2026 at 02:03 AMInvestment Rating
Neutral
Overall Score: 60/100
Rating Breakdown:
Stock Score Analysis
Stock Score: 532
Comprehensive Quality Assessment
Component Breakdown:
Valuation Metrics
| P/E Ratio | 25.78 |
| P/B Ratio | 2.58 |
| P/S Ratio | 1.60 |
| EPS | $10.46 |
| Beta | 0.97 |
| Shares Outstanding | 82.90M |
| 52-Week High | $293.72 |
| 52-Week Low | $209.38 |
| SMA 50 | $270.13 |
| SMA 200 | $266.33 |
| Dividend Yield | 1.07% |
| Annual Dividend | $2.88 |
| Next Earnings | April 28, 2026 12:30 PM ET |
Financial Ratios
| Gross Margin | 28.2% |
| Operating Margin | 10.7% |
| Net Margin | 6.3% |
| ROE | 10.3% |
| ROA | 4.8% |
| Debt/Equity | 0.84 |
| Current Ratio | 1.42 |
| Quick Ratio | 1.23 |
Balance Sheet
| Total Assets | $18.39B |
| Total Liabilities | $9.76B |
| Total Equity | $8.62B |
|
|
|
| Cash | $532.30M |
| Total Debt | $7.20B |
| Net Debt | $6.67B |
Income Statement
| Revenue | $13.95B |
| Gross Profit | $3.73B |
| Operating Income | $1.52B |
| Net Income | $876.50M |
|
|
|
| EBITDA | $2.01B |
| Revenue/Share | $169.11 |
Cash Flow
| Operating CF | $1.64B |
| CapEx | $434.50M |
| Free Cash Flow | $1.21B |
|
|
|
| Book Value/Share | $104.69 |
| Tangible Book/Share | $-21.20 |
| Equity/Share | $104.48 |
Technical Indicators
| RSI (14) | 40.62 Neutral |
| MACD |
2.00
Signal: 3.80
|
| Volatility | 31.33% |
| Trading Signal | Bearish |
Performance & Returns
| 1 Year | +7.95% |
| Sharpe Ratio | 0.31 Fair |
| Volatility (Ann.) | 24.38% Moderate |
| LH (1Y) | +7.95% |
| S&P 500 (1Y) | +13.03% |
| Alpha (Excess Return) | -5.08% |
Sector Comparison (Healthcare)
| Metric | LH | Sector Avg | Percentile |
|---|---|---|---|
| P/E Ratio | 25.78 | 27.69 | 49% |
| P/B Ratio | 2.58 | -19.57 | 43% |
| ROE (%) | 10.28% | -9.48% | 36% |
| Net Margin (%) | 6.28% | 9.38% | 28% |
| Stock Score | 532 | 544.0 | 34% |
| 1Y Return (%) | +7.95 % | +8.15 % | 56% |
📊 Historical Price Analysis (Last 200 Days)
Loading chart...
Technical Analysis
| Ticker | Close | SMA 5 | SMA 8 | SMA 13 | SMA 50 | SMA 200 | RSI (14) | MACD | Volatility (%) | Volume | Signal | SMA Decision |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| LH | $269.67 | $278.64 | $281.37 | $281.73 | $269.57 | $266.19 | 40.62 | 2.00 | 31.33% | 113780 | Strong Short | Bearish Stack |
Candlestick Patterns
There wasn't any recognizable pattern for the LH stock
News Sentiment
| 📊 Ticker | 📰 Headline | 💭 Sentiment | 📡 Source | 🔗 URL |
|---|---|---|---|---|
| LH | Labcorp Holdings (LH) is a Top-Ranked Value Stock: Should You Buy? | Neutral | zacks.com | Read More |
| LH | Is This the Right Time to Hold Labcorp Stock in Your Portfolio? | Neutral | zacks.com | Read More |
| LH | Labcorp Expands Collaboration with PathAI to Deploy FDA-Cleared Digital Pathology Platform Nationwide | Neutral | prnewswire.com | Read More |
| LH | Raiffeisen Bank International AG Purchases Shares of 3,068 Labcorp Holdings Inc. $LH | Neutral | defenseworld.net | Read More |
| LH | Why Labcorp Holdings (LH) is a Top Momentum Stock for the Long-Term | Neutral | zacks.com | Read More |
Recent Insider Trading
No recent insider trading data available for LH
Company Information
Labcorp Holdings, Inc. provides laboratory services to help doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.
| CEO | Adam H. Schechter |
| Employees | 60900 |
| Country | US |
| IPO Date | 1990-03-29 |
| Exchange | NYSE |
| Website | https://www.labcorp.com |
| Sector | Healthcare |
| Industry | Medical - Equipment & Services |
Rating Metrics Explained
DCF Score (Discounted Cash Flow)
Measures the intrinsic value of the stock based on projected future cash flows. A higher score indicates the stock is undervalued relative to its DCF valuation.
ROE Score (Return on Equity)
Evaluates how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better profitability and management effectiveness.
ROA Score (Return on Assets)
Measures how efficiently a company uses its assets to generate profit. A higher ROA means better asset utilization and operational efficiency.
D/E Score (Debt-to-Equity)
Assesses the company's financial leverage and risk. Lower debt-to-equity ratios indicate less financial risk and better balance sheet health.
P/E Score (Price-to-Earnings)
Compares stock price to earnings per share. A lower P/E ratio may indicate the stock is undervalued, while a higher ratio could suggest overvaluation or growth expectations.
P/B Score (Price-to-Book)
Compares market price to book value per share. Lower P/B ratios may indicate undervaluation relative to the company's net asset value.
Rating Recommendations:
Each metric is scored on a scale of 1-5, where the scores are determined by comparing the company's performance against industry benchmarks and historical data:
-
Strong Buy (5/5): Excellent score - strong positive indicator
- The metric significantly outperforms industry averages (top 20% of companies)
- Indicates exceptional financial health or attractive valuation in that category
-
Buy (4/5): Good score - positive indicator
- Above-average performance (top 40% of companies)
- Shows strong fundamentals with room for improvement
-
Neutral (3/5): Average score - neutral indicator
- Performance in line with industry median (middle 20%)
- Neither significantly positive nor negative signal
-
Sell (2/5): Below average - negative indicator
- Below-average performance (bottom 40% of companies)
- Suggests weakness in this particular metric
-
Strong Sell (1/5): Poor score - strong negative indicator
- Significantly underperforms industry (bottom 20%)
- Indicates potential risk or overvaluation in that category